Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P43652

UPID:
AFAM_HUMAN

ALTERNATIVE NAMES:
Alpha-albumin

ALTERNATIVE UPACC:
P43652; A8K3E1; Q32MR3; Q4W5C5

BACKGROUND:
Afamin, identified as Alpha-albumin, functions as a vital carrier for hydrophobic molecules, ensuring their solubility and activity in the body. It specifically supports lipidated Wnt family members, which are key to various biological processes. Moreover, Afamin's interaction with vitamin E, facilitating its transport, especially across the blood-brain barrier, underscores its importance in neuroprotection and antioxidant defense mechanisms.

THERAPEUTIC SIGNIFICANCE:
Exploring Afamin's multifaceted role in biological systems, particularly its contribution to Wnt signaling and vitamin E transport, could unveil novel therapeutic avenues. Its pivotal role in these processes makes it a promising target for developing treatments for neurological conditions and diseases linked to Wnt pathway abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.